What are traditional Chinese medicine stocks and pharmaceutical leading stocks?

What are traditional Chinese medicine stocks and pharmaceutical leading stocks?

What are the leading stocks of stock medicine? Pharmaceutical leading stock refers to the leading enterprise in the pharmaceutical industry, which has strong R&D, production and sales capabilities. With excellent product quality and innovative drug R&D strength, what are the leading stocks of stock medicine brought by the following small series? Let's take a look, hoping to bring some reference.

What are the leading stocks of stock medicine?

Leading pharmaceutical stocks are:

1, Jingfeng Medicine: pharmaceutical leading stock. On February 2, 20 18, the company announced that it had communicated with the FDA of the United States on the international multi-center phase III clinical trial of the company's anti-PD- 1 antibody SHR-12 1 0 combined with apatinib mesylate for the first-line treatment of liver cancer, which will be held in the United States, Europe and China.

2. Xianghai Pharmaceutical: pharmaceutical leading stock. Guangzhou Baiyun Mountain Pharmaceutical Group Co., Ltd. is a listed company controlled by Guangzhou Pharmaceutical Group Co., Ltd. (A shares 600332, H shares 00874), which is mainly engaged in (1) R&D, manufacturing and sales of Chinese and western medicines, chemical raw materials, natural medicines, biomedicine and intermediates of chemical raw materials; (two) the wholesale, retail and import and export business of western medicine, Chinese medicine and medical devices; (3) production and sales of R&D health products; And (4) investment in health industries such as medical services, health management, health care and old-age care.

3. China Resources Sanjiu: pharmaceutical leading stock. The profit of 20 15 in the pharmaceutical industry is expected to be 260.2 billion yuan, up 1 1.9% year-on-year, and the growth rate dropped by 0.4 percentage points year-on-year.

4. Kunyao Group: pharmaceutical leading stock. Sinopharm Co., Ltd. plans to actively develop the e-commerce industry, expand to the mobile APP "Sinopharm Online", add a "Sinopharm Online" channel, improve the public attention of Sinopharm Mall, deal with the loosening of online prescription drugs, and start preparing for the BtoC model. Previously, Sinopharm Mall, a B2B pharmaceutical e-commerce trading platform independently developed and operated by the company, was officially put into trial operation in June 20 13, and the commodities were classified into medicines, food, oral products, family planning products, medical devices, cosmeceuticals and so on.

5. Pharmaceutical leading stocks. The leading pharmaceutical outsourcing industry in China is CRO CMO Integrated Company, which was the earliest engaged in pharmaceutical R&D and production outsourcing in China. The senior management team has more than 200 authorized and pending patent achievements. Its main business is an all-round and integrated platform service for the discovery, research and development and production of small molecular chemical drugs, and provides research and development, production and supporting services for various new drugs for global pharmaceutical enterprises in the form of a whole industry chain platform; The company also provides overseas medical equipment testing and overseas precision medical R&D and production services.

Other pharmaceutical concept stocks include Haichen Pharmaceutical, Beida Pharmaceutical, Changshan Pharmaceutical, Fuan Pharmaceutical, Zhendong Pharmaceutical, Huaren Pharmaceutical and Laimei Pharmaceutical.

15 dual potential medicine unit (attached table)

1, Hengrui Pharma (chemical pharmacy)

Current price: 40.95, total market value: 2610.90 billion, circulating market value: 2610.20 billion, and 5438+0: 0.66 in the third quarter of 2026.

Theme concept: domestic chemical pharmacy, innovative drug leader. A-share pharmaceutical stocks with the largest market value.

Main business: drug research and development, production and sales.

2. Huahai Pharmaceutical (Chemical Pharmaceutical)

Current price: 20.99, total market value: 31.300 million, circulating market value: 30.5 billion, 20265438 third quarter +0:0.4 1.

Theme concept: the leading enterprise in the domestic characteristic API industry, the largest supplier of micropowder and sartan drugs in the world.

Main business: manufacturing and sales of tablets, hard capsules, APIs and pharmaceutical intermediates.

3. tonghua dongbao (Chemical Pharmacy)

Current price: 10. 15, total market value: 20.6 billion, circulating market value: 20.6 billion, 202 1 third quarter: 0.52.

Theme concept: domestic insulin leading stocks.

Main business: production and sales of Chinese and western medicines, biological products and plastic building materials.

4. WuXi PharmaTech (Pharmaceutical R&D)

Current price: 104.80, total market value: 309.8 billion, circulating market value: 266.9 billion, third quarter of 20265438 +0: 1.22.

Theme concept: CXO is the leader of the complete industrial chain, small molecule drugs are preclinical CRO, and domestic chemical pharmaceutical CMO ranks first.

Main business: the main business is the all-round and integrated platform service for the discovery, research and development and production of small molecular chemicals, and provides research and development, production and supporting services for various new drugs for global pharmaceutical enterprises in the form of the whole industry chain platform; In addition, the issuer also provides overseas medical device testing and overseas precision medical R&D and production services.

5. Zhao Yan New Drug Company (R&D Pharmaceutical)

Current price: 96.88, total market value: 36.9 billion, circulating market value: 3 1 100 million, 5438+0: 0.95 in the third quarter of 2026.

Subject concept: drug non-clinical safety leader, drug preclinical research service.

Main business: preclinical drug research services focusing on non-clinical drug safety evaluation services, sales of experimental animals and ancillary products.

6. Mindray Medical (medical equipment)

Current price: 323.28, total market value: 393 billion, circulating market value: 393 billion, third quarter of 20265438 +0: 5.48.

Theme concept: leading medical devices in China.

Main business: engaged in research and development, manufacturing, marketing and service of medical devices, always oriented to customer needs, and committed to providing quality products and services to medical institutions around the world.

7. Kailitai (Medical Devices)

Current price: 9. 10, total market value: 6.553 billion, circulating market value: 65.2 1 100 million, third quarter of 20265438 +0: 0.28.

Subject concept: Vertebroplasty minimally invasive interventional surgery system, orthopedic surgical instrument faucet.

Main business: R&D, producing and selling minimally invasive interventional surgery system for vertebroplasty.

8. Shouxian Valley (Chinese patent medicine)

Current price: 52.46, total market value: 8 billion, circulating market value: 8 billion, third quarter of 20265438 +0: 0.58.

Theme concept: China Lingzhi Dragon Head.

Main business: engaged in the cultivation, planting, processing and sales of rare Chinese herbal medicines such as Ganoderma lucidum and Dendrobium candidum.

9. Taiji Group (Chinese patent medicine)

Current price: 18.86, total market value:150 million, circulating market value:150 million, 202 1 third quarter: 0.45.

Theme concept: one of the leading Chinese patent medicines, the leading Chinese patent medicine plate in the early stage, has greatly improved its performance expectation.

Main business: production and sales of Chinese patent medicines, western medicines, health products, medical packaging products and medical devices, and import and export of raw materials, Chinese herbal medicines and medical packaging.

10, Jiang Zhong pharmaceutical (Chinese patent medicine)

Current price: 1 1.8 1, total market value: 7.440 billion, circulating market value: 7.373 billion, 20265438 third quarter +0: 0.72.

Theme concept: One of the leading Chinese patent medicines, an old OTC enterprise, Jiang Zhong brand Jianwei Xiaoshi tablets.

Main business: engaged in the production, research and development and sales of drugs and health care products.

1 1, general policy medical treatment (medical service)

Current price: 1 1.8 1, total market value: 47.6 billion, circulating market value: 47.6 billion, 20265438 third quarter +0: 1.93.

Theme concept: domestic oral medical leading stock.

Main business: investment management, medical device management, import and export business, technology development, technical consultation, technical training and technical services, and all other legal projects that do not need to be reported for approval.

12, Weining Health (Medical Services)

Current price: 1 1.5 1, total market value: 24.7 billion, circulating market value: 20.8 billion, 20265438 third quarter +0: 0. 12.

Theme concept: domestic medical informatization (cloud platform) leading stock.

Main business: The company is mainly engaged in the research and development, sales and technical services of medical software, providing overall solutions for the informatization of medical and health industry.

13, our new science and technology (COVID-19 specific drug concept)

Current price: 5.78, total market value: 4.272 billion, circulation market: 4.272 billion, third quarter of 20265438+0.0.108.

Theme concepts: asset injection, COVID-19 specific drugs, performance growth expectation. Sichuan Jiuling Pharmaceutical Co., Ltd., a wholly-owned subsidiary, is the largest manufacturer of ritonavir, an anti-HIV drug in China, and ritonavir is an important raw material for Huirui Xinguan oral specific drug.

Main business: production and sales of chemical raw materials, nucleoside (acid) and amino acid biochemical products; Edible flavoring agent, flavoring product, etc.

14, marine life (concept of specific drugs in COVID-19)

Current price: 34.58, total market value: 2.075 billion, circulating market value:1.407 billion, 20265438 third quarter +0: 1. 16.

Theme concept: The manufacturer of ethyl trifluoroacetate, an important raw material of Pfizer COVID-19 Pharmaceutical, and its pricing is relatively high.

Main business: engaged in the production and sales of chemical raw materials such as inorganic salts and veterinary raw materials.

15, frontier biology (specific medical concepts in COVID-19)

Current price: 15.92, total market value: 5.727 billion, circulating market value: 2.993 billion, third quarter of 20265438 +0: -0.49.

Subject concept: A new anti-COVID-19 drug FB200 1 for injection has been carried out in the United States 1 clinical trial, and it has been approved to carry out 1 clinical bridging trial in China.

Main business: Committed to R&D, developing, producing and selling innovative drugs, which are the main unmet clinical needs.

Do not make recommendations or suggestions, investment is risky, and you need to be cautious when entering the market.

What Chinese medicine leading stocks are there?

Chinese medicine leading stocks are:

1, Yunnan Baiyao 000538: It is a company mainly engaged in chemical raw materials, chemical preparations, Chinese patent medicines, Chinese herbal medicines and biological products. Its circulation market value ranks first in the industry, reaching 8210.97 billion yuan, with a price-earnings ratio of 24.28;

2. Pien Tze Huang 600436: It is a company mainly engaged in the production and sales of buccal tablets, tablets, granules and other medical products and tourist commodities, with the circulation market value ranking second in the industry, reaching 64.283 billion yuan, with a price-earnings ratio of 39.74;

3. Baiyunshan 600332: One of the most valuable pharmaceutical brands in China, with the market value in circulation ranking third in the industry, reaching 42.494 billion yuan, and the price-earnings ratio 1 1.46.

In addition, there are Tongrentang 600085, Tasly 600535, Jichuan Pharmaceutical 600566, China Resources Sanjiu 000999, Dong 'e Ejiao 000423 and so on.

What are the leading stocks of API stocks?

Chinese medicine leading stocks include Guangxin Pharmaceutical (3005 19), Angel Pharmaceutical (00210/8), Shenlong Rongfa (300534), Yunnan Baiyao (00538), Tongrentang (600085) and Pien Tze Huang.

Extended information:

1. Other Chinese medicine concept stocks include:

1. Taian Tang: In the past seven trading days, Taian Tang fell by 20.26%, with the highest price of 6.48 yuan, and the total market value fell by 8,565,438 million yuan, a decrease of 20.26%.

2. Yisheng Pharmaceutical: Looking back on the past seven trading days, Yisheng Pharmaceutical has fallen for six consecutive days. The whole period fell by 9.38%, with the highest price of 8.58 yuan and the lowest price of 9. 14 yuan, with a total of 40196,600 lots.

3. Yiling Pharmaceutical: The share price of Yiling Pharmaceutical fell 15.08% in recent 7 days, and rose by 2.26% in 2022, with the highest price of 25.76 yuan and the market value of 34.784 billion yuan.

Second, the investment logic of Chinese medicine enterprises:

With the continuous support of recent national policies, the Chinese medicine sector may be favored by market investors in the short term.

Innovation and consumption are the two main lines of the long-term development direction of Chinese medicine industry. At present, the listed Chinese medicine companies that have done well include Yiling Pharmaceutical, Yunnan Baiyao, Pien Tze Huang and other companies with strong general consumption attributes.

It is suggested to pay attention to the following transformation opportunities: (1) transform innovative Chinese medicine R&D enterprises to develop clinically necessary drugs with excellent curative effect by using evidence-based medicine; Transform the common consumer goods field of "medical insurance immunization" and find new growth points; Transformation of low-cost and high-quality Chinese herbal medicine suppliers, especially the artificial substitution of scarce Chinese herbal medicine resources.

Three. Jiuzhitang: The company's predecessor, Old Jiuzhitang Pharmacy, was founded in 1650, and Jiuzhitang and Youbo are well-known trademarks in China; "Nine-match inferior Tang Zhi" was recognized as "China's time-honored brand" by the Ministry of Commerce; Jiuzhitang traditional Chinese medicine culture is listed in the national intangible cultural heritage protection catalogue.

What leading stocks are there in pharmaceutical manufacturing?

The leading stocks in pharmaceutical manufacturing are: 600085 Tongrentang, 000538 Yunnan Baiyao, 60077 1 Tibet Pharmaceutical, 600285 Ling Rui, 000423 Dong 'e Ejiao, 000650 Renhe Pharmaceutical, 600422 Kunyao, 60077 1 Dongsheng Technology, 000597 Northeast Pharmaceutical. 600488 Tianyao Co., Ltd., 0020 19 Xinfu Pharmaceutical, 600252 Zhongheng Group, 600276 Hengrui Pharma, 000952 Guangji Pharmaceutical, etc.